Aberrant activation of c-kit proto-oncogene contributes to abnormal cell proliferation by altering the tyrosine kinase signaling and constitutes a crucial impetus for leukemogenesis. Epigenetic silencing of tumor-suppressive microRNAs (miRNAs) is a key oncogenic mechanism for the activation of oncogenes in tumors. In this study, several miRNAs potentially binding to the 3 0 -untranslated region of human c-kit mRNA were screened by luciferase reporter assays. Among these miRNAs, miR-193a was embedded in a CpG island and epigenetically repressed by promoter hypermethylation in acute myeloid leukemia (AML) cell lines and primary AML blasts, but not in normal bone marrow cells. Importantly, miR-193a levels were inversely correlated with c-kit levels measured in 9 leukemia cell lines and 27 primary AML samples. Restoring miR-193a expression in AML cells harboring c-kit mutation and/or overexpression, either by synthetic miR-193a transfection or by DNA hypomethylating agent 5-azacytidine (5-aza) treatment, resulted in a significant reduction in c-kit expression at both RNA and protein levels and inhibition of cell growth. The growth-inhibitory activity of miR-193a was associated with apoptosis and granulocytic differentiation. Moreover, 5-aza-induced c-kit reduction could be partially blocked by miR-193a inhibitor, leading to a reversal of antiproliferative and proapoptotic effects of 5-aza. These data reveal a critical role for methylation-repressed miR-193a in myeloid leukemogenesis and the therapeutic promise of upregulating miR-193a expression for c-kit-positive AML.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great variability in clinical course and response to therapy, as well as in the genetic and molecular basis of pathology (Renneville et al., 2008) . Besides the major cytogenetic abnormalities, gene mutations constitute key events in AML pathogenesis. The c-kit proto-oncogene encodes a transmembrane glycoprotein of the type III receptor protein tyrosine kinase family, whose ligand is stem cell factor (Blume-Jensen and Hunter, 2001; Reilly, 2003) . The ligand binding triggers c-kit dimerization and transphosphorylation, leading to activation of downstream signaling pathways involved in proliferation, differentiation, migration and survival of hematopoietic stem cells. Overexpression of c-kit is reported in approximately 60-80% of all AML patients (Kindler et al., 2004; Heidel et al., 2007) and c-kit mutations are observed in more than 40% of AML patients with inv(16) and t(8;21) (Beghini et al., 2004; Cairoli et al., 2006; Paschka et al., 2006; Schnittger et al., 2006) . These gain-of-function alterations render constitutive and ligand-independent c-kit activation, resulting in aberrant signaling which is a crucial impetus for leukemogenesis and associated with a poor outcome in AML (Lennartsson et al., 2005; Boissel et al., 2006; Cairoli et al., 2006; Schnittger et al., 2006; Jiao et al., 2009) . Therefore, c-kit is a promising therapeutic target in AML. Despite that the downstream signaling pathways of c-kit have been identified, the upstream regulatory mechanisms remain incompletely understood. More detailed information regarding the endogenous upstream regulators of c-kit will facilitate the specific and efficient targeted therapy for AML patients.
MicroRNAs (miRNAs) are an abundant class of small non-protein-coding RNAs that suppress gene expression at the posttranscriptional level through blocking translation or degrading target mRNAs (Ambros, 2004; Bartel, 2004) . The miRNAs regulate diverse biological processes and each of them probably controls hundreds of gene targets. In humans, deregulation of miRNAs expression contributes to the multistep processes of tumorigenesis either as oncogenes or as tumor suppressor genes (Esquela-Kerscher and Slack, 2006; Osada and Takahashi, 2007; Fabbri et al., 2008) .
Tumor-specific downregulation of subsets of miRNAs has been described in the initiation and progression of leukemia (Tenen, 2003; Marcucci et al., 2008; ). In addition, evidence has emerged that epigenetic mechanisms, typically through methylation of CpG islands within the primary promoter region of miRNAs, play a crucial role in the downregulation of tumor suppressor miRNAs and contribute to malignant transformation during leukemogenesis (Bueno et al., 2008; Agirre et al., 2009; Roman-Gomez et al., 2009) .
Given the critical prognostic impact of c-kit and the emerging role of miRNAs in AML, we hypothesized that certain miRNAs might repress c-kit expression and function as methylation-silenced tumor suppressor genes in AML. To identify such miRNAs, we screened several miRNAs potentially binding to the 3 0 -untranslated region (3 0 -UTR) of human c-kit mRNA. Among these miRNAs, miR-193a was embedded in a CpG island and epigenetically repressed by promoter hypermethylation in leukemia cell lines and primary AML blasts, but not in normal bone marrow (BM) cells. Importantly, miR-193a levels were inversely correlated with c-kit levels measured in the abovementioned AML cells. By targeting c-kit proto-oncogene, miR-193a inhibited the growth of AML cells harboring c-kit mutation and/or overexpression, and induced cellular apoptosis and granulocytic differentiation. These results suggest a critical role for methylation-repressed miR-193a in myeloid leukemogenesis and provide a pharmacologic rationale through upregulating miR-193a expression as a prospective adjunctive therapy for c-kit-positive AML.
Results
Six miRNAs potentially interact with the 3 0 -UTR of human c-kit mRNA TargetScan Human 5.1 software (http://www.targetscan. org/; Lewis et al., 2005; Grimson et al., 2007) was used to analyze the miRNAs targeting c-kit. As shown in Figure 1a , 15 miRNAs potentially bind to the 3 0 -UTR of human c-kit mRNA. The binding sites of these miRNAs are conserved across species. To validate the computational data, 1599 bp of the human c-kit 3 0 -UTR was subcloned downstream of the firefly luciferase-coding region. The construct was cotransfected into 293T cells with either miRNA expression plasmid or empty vector pcDNA3.0. Luciferase activity was measured at 48 h after each transfection. Cells cotransfected with each miRNA expression plasmid exhibited approximately 35-70% reduction of the luciferase activity with respect to those cotransfected with empty vector pcDNA3.0 (Figure 1b) . To further confirm the above data and identify the target site of each miRNA, four deletants of c-kit 3 0 -UTR were subcloned downstream of the firefly luciferase-coding region ( Figure 1a) . The resulting constructs, pGL3-KIT mut-1, -2, -3 and -4 were, respectively, cotransfected into 293T cells with miRNA expression plasmid or pcDNA3.0. Luciferase activity in respective cells was then measured. Compared with the reduction in luciferase activity observed when the authentic c-kit 3 0 -UTR was cotransfected with miR-218, -193a, -193b, -137, -221 or -222 expression plasmid, deletion of the corresponding binding site of each of these miRNAs in the c-kit 3 0 -UTR resulted in recovery of luciferase activity, indicating that they were no longer able to bind to the 3 0 -UTR with the same avidity ( Figure 1c ). All these data suggested that the abovementioned six miRNAs could hybridize with their predicted binding sites in the c-kit 3 0 -UTR, and deletion of their binding sites would result in enhanced luciferase activity. In this study, we focused on miR-193a for the reason that it was embedded in a CpG island region and might be regulated by DNA methylation.
MiR-193a downregulates c-kit expression in AML cell lines
To confirm that miR-193a could downregulate endogenous c-kit expression in AML cells, we transfected synthetic miR-193a mimic or negative control (NC) into two human myeloid leukemia cell lines (Kasumi-1 and K562) and measured the levels of c-kit mRNA and protein by quantitative real-time PCR (qRT-PCR) and western blot, respectively. The Kasumi-1 and K562 cell lines, respectively, carry mutant and wild-type c-kit (Larizza et al., 2005) , and both cell lines expressed very low levels of miR-193a (Supplementary Table S1 ). First, we monitored transfection efficiency using carboxyfluorescein(FAM)-labeled miRNA mimic. About 50% of Kasumi-1 and 90% of K562 were FAM-positive at 48 h after transfection, as measured by flow cytometry (Figure 2a) , indicating that the synthetic miRNAs were efficiently transfected into the cells. Transfection of miR193a resulted in a marked reduction of endogenous c-kit mRNA levels in both cell lines, and the strongest effect was observed at 12 and 24 h after transfection, respectively (Figure 2b ). Consistent with this result, a significant downregulation of c-kit and phosphorylated c-kit protein levels was observed in these cells at 48 h after miR-193a transfection (no significant change was observed at 12 and 24 h, data not shown; Figure 2c ), These results indicated that miR-193a downregulated ckit expression in Kasumi-1 and K562 cells not only by inhibiting its mRNA translation but also by targeting its mRNA for degradation.
MiR-193a expression is downregulated in leukemia cell lines and primary AML samples and inversely correlated with c-kit expression To validate the correlation between miR-193a expression and endogenous c-kit expression, we detected their levels by qRT-PCR in a set of leukemia cell lines (Supplementary Table S1 ) and BM samples isolated from newly diagnosed AML patients (Table 1 ) and from healthy donors. As shown in Figure 3a , miR-193a was expressed at a lower level in leukemia cell lines (n ¼ 9; z ¼ 2.666, P ¼ 0.008) and primary AML samples (n ¼ 27; z ¼ 2.845, P ¼ 0.004) than in normal BM samples (n ¼ 11). Importantly, we found a significant inverse correlation between c-kit and miR-193a mRNA levels in the same cell lines and primary AML samples described above (r ¼ À0.82, P ¼ 0.007 and r ¼ À0.51, P ¼ 0.006, respectively; Figures 3b and c; Supplementary Table S1 ). Subsequently, we analyzed the expression levels of c-kit and miR-193a in sequential BM samples from four AML patients in clinical remission (Supplementary Table S2 ). The c-kit and miR-193a levels for each patient were set as 1 at the time of primary diagnosis. Their changes were, respectively, calculated at two follow-up time points for the individual patient. After induction therapy, the mean levels of miR-193a significantly increased, whereas the mean levels of c-kit gradually decreased (Figure 3d ). Taken together, these results suggested that miR-193a expression was inversely correlated with c-kit expression in AML cells.
Methylation-mediated transcriptional repression of miR-193a gene in AML cells
Using the miRNA database (http://www.mirbase.org/), a typical CpG island was identified around the region encoding precursor miRNA hsa-miR-193a (pre-miR-193a; Figure 4a ), suggesting that miR-193a was potentially regulated by DNA methylation. Our laboratory had identified a functional promoter region located at about 2000 bases relative to the 5 0 end of the pre-miR-193a (Li et al., unpublished data) . Therefore, we first analyzed the methylation status of CpGs located in this region by bisulfite genomic sequencing in the Kasumi-1 AML cell line and normal BM cells. Interestingly, the CpGs were densely methylated along the region from -657 to -158 bases upstream of the pre-miR-193a sequence in Kasumi-1 cells, whereas those along the region from -743 to -658 bases were fully unmethylated (Figure 4b, upper panel) . By contrast, only a few scattered CpGs along these two regions were methylated in the BM cells from a healthy donor (Figure 4b , lower panel).
To further identify whether the miR-193a CpG island was hypermethylated in a tumor-specific manner, we detected its methylation status by methylation-specific PCR analysis in a set of leukemia cell lines and BM samples isolated from AML patients (Supplementary  Table S3 ) and from healthy donors. Considering that the CpGs with dense methylation assembled in the MiR-193a represses c-kit proto-oncogene in AML X-N Gao et al region from -657 to -158 bases upstream of pre-miR-193a in Kasumi-1 cells, but not in normal BM cells, we speculated that it was this region that was more susceptible to be regulated by DNA methylation. Therefore, the primers for methylation-specific PCR analysis were designed within this region. As shown in Figure 4c , the miR-193a CpGs were significantly methylated in all the nine leukemia cell lines and AML patients (11 cases at initial diagnosis and 4 cases at relapse) tested. Methylation of miR-193a was also present in three of nine AML patients in complete remission (patient 6, 10 and 11).
In contrast, the miR-193a CpGs exhibited a complete absence of methylation in 11 healthy donors and a human non-tumor hepatic cell line LO2. To test whether DNA methylation participated in the regulation of miR-193a expression, we treated Kasumi-1 and K562 cells with DNA methyltransferase inhibitor 5-azacytidine (5-aza), and analyzed the changes of miR-193a expression by qRT-PCR. A significant dosedependent induction of miR-193a transcription was detected in both cell lines after incubation with 5-aza for 72 h (Figure 4d ), indicating that DNA methylation contributed to the transcriptional repression of miR-193a in the cells. As further proof of a correlation between methylation and miR-193a expression, we divided the above patient and control samples into two groups according to miR-193a methylation status, one with methylation (15 AML patients at initial diagnosis and relapse) and the other without methylation (11 healthy donors). The levels of miR-193a in the methylation group were significantly lower than those in the non-methylation group (z ¼ 2.578, P ¼ 0.01; Figure 4e ).
Restoration of miR-193a expression contributes to demethylation-induced c-kit repression in AML cell lines
Considering that miR-193a targeted and reduced c-kit expression, and itself was silenced by DNA methylation in AML cells, it was conceivable that demethylating treatment might downregulate c-kit levels through reactivating miR-193a expression. To address this issue, we treated Kasumi-1 and K562 cells with 5-aza and measured the levels of c-kit mRNA and protein by qRT-PCR and western blot, respectively. After 72 h, there was a 1.2-fold reduction in c-kit mRNA levels in Kasumi-1 cells treated with 5.0 mM 5-aza as compared with the control (Figure 5a, left panel) . Interestingly, we noticed a more significant downregulation of c-kit and phosphorylated c-kit protein levels in the cells upon 5-aza treatment (both twofold, as compared with the control; Figure 5b , left panel). Similar downregulation of c-kit mRNA and protein levels was observed in 5-azatreated K562 cells (Figures 5a and b, right panel) . These results suggested that posttranscriptional mechanisms such as miRNA-mediated regulation might participate in the 5-aza-induced c-kit repression in both cell lines. We validated this speculation by transfecting the 5-azatreated Kasumi-1 or K562 cells with synthetic miR-193a inhibitor or NC inhibitor. A significant upregulation of c-kit and phosphorylated c-kit protein levels was observed in the 5-aza-treated cells after miR-193a inhibitor transfection (Figure 5c ).
Overexpression of miR-193a reduces growth and induces apoptosis and differentiation in AML cell lines
To assess the biologic effects of miR-193a in AML, we transfected Kasumi-1 and K562 cells with miR-193a mimic or NC, and examined the cell growth curve by Cell Counting Kit-8 (Dojin Laboratories, Kumamoto, Japan) assay. It has been reported that imatinib mesylate (Gleevec, STI-571, Novartis Pharmaceuticals, Florham Park, NJ, USA), a selective tyrosine kinases inhibitor, inhibits growth of Kasumi-1 and K562 cells (Wang et al., 2005; Jacquel et al., 2007) . Therefore, we treated the cells with imatinib to serve as positive control. The cell growth of Kasumi-1 and K562 cell lines was inhibited by miR-193a transfection as compared with control (Figure 6a ), although the antigrowth activity of miR-193a was weaker than that of imatinib. Previous studies have shown that 5-aza can inhibit growth and trigger apoptosis in Kasumi-1 and K562 cells (Youssef et al., 2004; Berg et al., 2007; Flotho et al., 2009) , and as shown above, 5-aza could restore the expression of miR-193a in both cell lines. Therefore, we hypothesized that blocking the 5-aza-induced miR-193a reexpression could abrogate its antigrowth activity. To test this hypothesis, we determined the effect of 5-aza on cell growth of Kasumi-1 and K562 cell lines in the presence or absence of miR-193a inhibitor. The combined treatment of 5-aza with miR-193a inhibitor resulted in partial reversal of the 5-aza-induced growth inhibition ( Figure 6b) .
Next, we examined the effect of miR-193a on apoptosis as measured by Annexin V/7AAD assay (BD Biosciences PharMingen, San Diego, CA, USA). As shown in Figure 6c , miR-193a induced a 1.5-and 2.0-fold increase in apoptosis in Kasumi-1 and K562 cells, respectively, as compared with control. Moreover, miR-193a significantly enhanced the proapoptotic effect of 5-aza (1.2-and 1.4-fold, respectively, as compared with control). To determine whether abrogating the 5-aza-induced miR-193a reexpression could affect its proapoptotic effect, Kasumi-1 or K562 cells were transfected with miR-193a or NC inhibitor, then cultured with 5-aza. There was a 1.2-and 1.5-fold, respectively, reduction in apoptosis in both cell lines after miR-193a inhibitor transfection.
Finally, we measured the effect of miR-193a on the myeloid differentiation marker CD11b and CD15 expressions by flow cytometry. As shown in Figure 6d , Kasumi-1 and K562 cells transfected with miR-193a exhibited about 21 and 17% increase in CD11b expression, as well as 37 and 16% increase in CD15 expression, respectively. 
1 (3.7) c-kit mutation 4 (14.8) NRAS mutation 4 (14.8) FLT3 internal tandem duplication 2 (7.4) NPM1 mutation 2 (7.4) RUNX1 mutation 1 (3.7) GATA2 mutation 1 (3.7)
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow. a Leukemias were classified according to FAB classification (Bennett et al., 1985 Overexpression of miR-193a induces apoptosis and differentiation in primary AML blasts To further prove that miR-193a had a functional role in AML, we tested whether miR-193a could induce apoptosis and differentiation in primary leukemia blasts. Fresh primary blasts were isolated from BM samples of two newly diagnosed AML patients (Supplementary Table S4 ). Consistent with the data in cell lines, primary blasts infected with a lentiviral vector expressing miR-193a exhibited a 2.5-fold increase in miR-193a level and a 1.6-fold decrease in c-kit level after 6 days of culture (Figure 7a ), which resulted in primary blast differentiation as shown by the increased CD11b expression (about 2.2-fold; Figure 7b ). Moreover, miR-193a overexpression induced a 1.5-fold increase in apoptosis in primary blasts at 72 h, as compared with control ( Figure 7c ).
Discussion
Because methylation-mediated silencing of some tumor suppressor miRNAs is a key mechanism for the activation of oncogenes in diverse tumor types (Saito et al., 2006; Bueno et al., 2008; Datta et al., 2008; Lujambio et al., 2008; Agirre et al., 2009; Lee et al., 2009; Roman-Gomez et al., 2009) , the similar mechanism might also have a role in the uncontrolled activation of c-kit proto-oncogene during leukemogenesis. The present study was designed to identify the tumor suppressor miRNAs that directly targeted c-kit but were silenced by tumor-specific DNA methylation in AML. Previous studies have shown that miR-221 and -222 directly target the 3 0 -UTR of c-kit mRNA and suppress its expression (Felli et al., 2005) , and there is an indirect role of miR-29b in modulating c-kit expression in c-kit-driven leukemia (Liu et al., 2010) . Here, we provide the first evidence that methylation-mediated deregulation of miR-193a abrogates its suppression on abnormal c-kit activity, and thereby contributes to leukemic growth in c-kit-positive AML. By using miRNA reverse screening, we initially identified six miRNAs that directly targeted the 3 0 -UTR of c-kit mRNA, including miR-218, -193a, -193b, -137, -221 and -222 . Among these miRNAs, miR-193a and -137 were located in CpG islands and thus susceptible to methylation-mediated silencing. In fact, a previous report has found that miR-193a and -137 are silenced by DNA methylation in oral cancer, and the transcription factor E2F6 and cyclin-dependent kinase 6 are their respective targets (Kozaki et al., 2008) . In our study, c-kit was proved to be a new potential target of miR-193a, as enhanced miR-193a expression significantly reduced its protein and mRNA levels in AML cells. Because nonsignificant reduction of c-kit by miR-137 overexpression was observed in both Kasumi-1 and K562 cell lines (data not shown), we selectively focused on miR-193a in the succeeding study.
Through comparison analysis of gene expression between AML and normal cells, we identified that miR-193a levels were dramatically and specifically downregulated in AML cell lines and primary AML blasts. Importantly, we found a significant inverse correlation between miR-193a and c-kit expression in AML cells, which confirmed their regulatory relationship described in the abovementioned in vitro assays. To analyze whether DNA methylation participated in the aberrant downregulation of miR-193a expression in AML, we measured the methylation status of CpG sites upstream of miR-193a gene in a set of leukemia cell lines and primary AML samples. Compared with healthy donors, the CpGs were densely methylated in all the tested cell lines and primary AML samples, which was consistent with the very low levels of miR-193a in AML.
Demethylating treatment led to a significant induction of miR-193a expression in AML cells, indicating a crucial role for DNA methylation in regulating miR-193a expression. The restoration of miR-193a levels by demethylating treatment and the inverse correlation between miR-193a levels and its methylation status suggested that tumor-specific DNA methylation was responsible, at least in part, for the abnormal downregulation of miR-193a in AML. Notably, miR-193a methylation was also present in a fraction of AML patients in complete remission. It has been reported that many patients with acute leukemia in clinical remission harbor increased levels of aberrant DNA methylation, and methylation analyses can be used as molecular markers for minimal residual disease (Agrawal et al., 2007) . In our study, because we detected a recurrence of c-kit overexpression that was specific for the malignant cell clone in these patients (data not shown), there might The methylation-mediated downregulation of miR-193a in AML cells and the significant suppressive effect of miR-193a on c-kit proto-oncogene strongly suggested a possibility for miR-193a as a methylationsilenced tumor suppressor in AML. In our study, we provided insights about the biologic effects of miR-193a overexpression in AML cells. Restoring miR-193a expression in AML cells, either by synthetic miR-193a transfection or by 5-aza treatment, significantly reduced the mRNA, protein and phosphorylated protein levels of c-kit, thereby leading to marked inhibition of cell growth. The growth-inhibitory activity of miR-193a was associated with apoptosis and granulocytic differentiation. Together, these results support an important tumor suppressor function of miR-193a in AML by targeting c-kit proto-oncogene. It has been reported that Kasumi-1 cells exhibit a high sensitivity to 5-aza-induced antigrowth and proapoptotic effects in vitro, and several potential target genes of this demethylating treatment have been identified (Berg et al., 2007; Flotho et al., 2009) . In our study, 5-aza-induced c-kit reduction could be partially blocked by the synthetic miR-193a inhibitor, resulting in a reversal of antigrowth and proapoptotic effects of 5-aza on Kasumi-1 and K562 cell lines. These results suggested that demethylation and reactivation of miR-193a were among the molecular events associated with 5-aza-induced growth inhibition and apoptosis in these cells. Notably, cotreatment with 5-aza and synthetic miR-193a mimic exerted synergistic apoptotic effects in Kasumi-1 and K562 cells, suggesting that miR-193a might be introduced as a potential adjuvant therapy when using 5-aza in c-kit-positive AML.
In conclusion, our study demonstrates that miR-193a is embedded in a densely methylated CpG island in AML cells in a tumor-specific manner. This miRNA directly targets c-kit proto-oncogene, and its restoration reduces the mRNA, protein and phosphorylated protein levels of c-kit and inhibits the growth of AML cells.
DNA methylation, miR-193a and c-kit may constitute a switch-regulating pathway, which have an important role in cell differentiation and development. In the process of hematopoietic stem-and progenitor-cell development, hypomethylation of miR-193a CpG island is associated with physiological levels of miR-193a expression. By targeting the 3 0 -UTR of c-kit mRNA, miR-193a suppresses abnormal c-kit expression and activation, thereby blocking leukemogenesis. Hypermethylation of miR-193a CpG island results in downregulation of miR-193a expression. In this situation, the aberrant c-kit activity is inefficiently eliminated and thereby promotes the uncontrolled proliferation of malignant cells, which ultimately contributes to leukemic transformation (Figure 8) . Overall, the methylation- mediated silencing of miR-193a has a pivotal role during myeloid leukemogenesis, and strategies to restore miR193a expression and its subsequent repression on the aberrant activation of c-kit proto-oncogene will be valuable for c-kit-positive AML therapy.
Materials and methods

Cell lines and cell cultures
Human embryonic kidney 293T cells were maintained in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS (HyClone Laboratories, Logan, UT, USA). Human leukemia cell lines, Kasumi-1, K562, SKNO-1, Molt4, HL-60, KG-1, U937, NB4 and THP-1 were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% FCS. Fresh primary blasts from BM samples of two newly diagnosed AML patients were isolated and cultured as previously described .
Clinical samples
Mononuclear cells from BM samples of AML patients and healthy donors were prepared by Ficoll-Hypaque (Sigma-Aldrich, St Louis, MO, USA) gradient centrifugation. This study was carried out in accordance with the principles of Declaration of Helsinki, and was approved by the human subject ethics committee in our hospital. Signed informed consent was obtained from each subject.
Firefly luciferase reporter constructs and luciferase assays
The wild-type human c-kit 3 0 -UTR fragment containing predicted miRNA target sites was PCR amplified using the HepG2 cell genomic DNA as template. Mutant 3 0 -UTRs with deletions of 7 bp from the site of perfect complementarity of ckit gene were generated by overlap extension PCR method. Primer sequences are shown in Supplementary Table S5 . Both wild-type and mutant 3 0 -UTRs were cloned downstream of firefly luciferase-coding region between the PstI and EcoRI sites of a modified pGL3-control plasmid. The authenticity and orientation of the inserts relative to the luciferase gene were confirmed by sequencing. Luciferase assays were performed as previously described (Liu et al., 2008) . The transfection mixtures, contained 100 ng of firefly luciferase reporter plasmid, 10 ng of pRL-TK (Promega, Madison, WI, USA) and 400 ng of miRNA expression plasmid (Cui et al., 2007) , were transfected into 293T (5 Â 10 4 ) cells in 24-well plates using FuGENE HD transfection reagent (Roche Applied Science, Indianapolis, IN, USA). Cells were collected at 48 h after transfection, and luciferase activity was measured using a dual-luciferase reporter assay system (Promega).
Synthetic miRNA transfection and miR-193a lentivirus infection
The miR-193a mimic, inhibitor and NCs, designed and synthesized by GenePharma (Shanghai, China; Supplementary  Table S6) , were transfected into leukemia cell lines using HiPerFect transfection reagent (QIAGEN, Valencia, CA, USA) according to protocol. Cells were collected at 48 h after transfection. The miR-193a lentivirus was purchased from Sunbio Medical Biotechnology (Shanghai, China). This construct consisted of the pre-miR-193a sequence and 100 bases of upstream-and downstream-flanking sequence cloned into the pGIPZ plasmid. Primary AML blasts were infected with the miR-193a lentivirus, with an efficiency of B15% as determined by green fluorescent protein measurement by fluorescence microscope (Supplementary Figure S1) . Empty lentivirus was used as a control.
RNA extraction and analysis Total RNA was extracted from cells using TRIzol reagent (Invitrogen). Small RNA was extracted using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA). The relative quantity of mature miR-193a-3p was measured on 10 ng of small RNA by qRT-PCR using the TaqMan miRNA Assays (Applied Biosystems, Foster City, CA, USA) according to protocol, and it was determined by the comparative Ct method (Livak and Schmittgen, 2001 ) using U6 small nuclear RNA levels for normalization. The relative quantity of c-kit was measured on 1 mg of total RNA by qRT-PCR using glyceraldehyde 3-phosphate dehydrogenase levels for normalization. Primer and probe sequences are shown in Supplementary Table S5 .
Western blot analysis
Total protein was extracted from cells using radio immunoprecipitation assay buffer (Sigma-Aldrich). Protein expression was analyzed by western blot using anti-c-kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-phosphorylated c-kit (Signalway Antibody, Pearland, TX, USA). The anti-b-actin (Santa Cruz Biotechnology) was used to normalize the amount of the analyzed samples.
Methylation analysis
Genomic DNA was extracted from cells using Wizard Genomic DNA Purification Kit (Promega). In all, 1 mg of DNA was modified with sodium bisulfite using an EpiTect Bisulfite Kit (QIAGEN). For bisulfite-sequencing analysis, 5 0 upstream flanking sequence from the pre-miR-193a was amplified by PCR using the bisulfite-treated DNA as template. Primer sequences are shown in Supplementary Table S5 . PCR products were subcloned and then sequenced. For methylation-specific PCR analysis, the methylation-specific and unmethylation-specific primers were designed by MethPrimer software (Li and Dahiya, 2002) , as shown in Supplementary  Table S5 .
Cell growth, apoptosis and differentiation assay Leukemia cell lines were transfected with miR-193a mimic and miR-193a inhibitor, or treated with 1.0, 2.5 and 5.0 mM of 5-aza (Sigma-Aldrich) and 2.5 mM of imatinib, respectively. The number of viable cells was assessed by Cell Counting Kit-8. For apoptosis assay, the cells were stained with Annexin V and 7AAD (BD Biosciences PharMingen) and analyzed by BD FACSCalibur flow cytometer. For differentiation assay, the cells were stained with anti-CD11b or anti-CD15 (BD Biosciences PharMingen), and analyzed by flow cytometry. Appropriate isotype controls were used simultaneously. The expression of CD11b in primary AML blasts, infected with empty vector or miR-193a lentivirus, was analyzed in green fluorescent protein-positive cells by flow cytometry at 6 days after infection.
Statistical analysis SPSS 15.0 software (SPSS Inc., Chicago, IL, USA) was used to process the data. Wilcoxon signed-rank test was selected to determine the difference of miR-193a expression among clinical samples. Student's t-test was applied to compare miR193a-induced changes with respective controls. Spearman's correlation coefficient (r) was used to determine the correlation between miR-193a and c-kit mRNA levels. A P-value of o0.05 was chosen as a threshold for statistical significance.
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